This site is intended for health professionals only

Published on 14 March 2008

Share this story:
Twitter
LinkedIn

Tie-up to examine siRNA molecules

teaser

Silence Therapeutics has announced it is to work with pharmaceutical giant AstraZeneca to development new ways to deliver siRNA molecules.

The firms will pool their expertise in the field, and both will be allowed to commercialise the products they develop.

They believe that solving problems around the successful delivery of siRNA molecules to different tissue sites could be crucial in helping to treat various different diseases.

Jeff Vick, CEO of Silence Therapeutics, said: “We are delighted to enter this new collaboration with AstraZeneca for the development of novel approaches for the delivery of siRNA molecules.

“This agreement highlights the significant progress we have made with our AtuPLEX platform, following our early realisation of the importance of delivery to the development of successful RNAi therapeutics.

“This deal also reflects the strong working relationship we have developed with AstraZeneca and the progress of our ongoing collaboration in the development of AtuRNAi molecules against a number of their targets.”

He added: “We look forward to continuing our work with AstraZeneca in this important therapeutic area, and are extremely excited about the potential of our AtuPLEX delivery technology today and its ability to be developed further so that it can become an even more significant value driver for Silence Therapeutics.”

Copyright © PA Business 2008

Silence Therapeutics



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn